NextCure (NASDAQ:NXTC) Shares Down 7.1% – Here’s Why

NextCure, Inc. (NASDAQ:NXTC)’s share price fell 7.1% during trading on Tuesday . The stock traded as low as $0.76 and last traded at $0.77. 1,091,424 shares traded hands during trading, an increase of 714% from the average session volume of 134,012 shares. The stock had previously closed at $0.83.

Wall Street Analyst Weigh In

Separately, HC Wainwright reduced their target price on NextCure from $8.00 to $4.00 and set a “buy” rating for the company in a report on Monday, November 11th.

NextCure Stock Up 3.4 %

The company’s 50-day moving average is $1.16 and its two-hundred day moving average is $1.38. The company has a market cap of $22.32 million, a P/E ratio of -0.38 and a beta of 0.63.

Institutional Investors Weigh In On NextCure

Several large investors have recently modified their holdings of the stock. Armistice Capital LLC bought a new position in NextCure in the 2nd quarter worth approximately $57,000. Geode Capital Management LLC lifted its holdings in shares of NextCure by 14.2% in the third quarter. Geode Capital Management LLC now owns 223,741 shares of the company’s stock worth $307,000 after buying an additional 27,812 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of NextCure by 15.4% in the second quarter. Renaissance Technologies LLC now owns 462,144 shares of the company’s stock valued at $735,000 after acquiring an additional 61,744 shares during the period. Affinity Asset Advisors LLC grew its stake in NextCure by 24.2% during the second quarter. Affinity Asset Advisors LLC now owns 1,687,955 shares of the company’s stock valued at $2,684,000 after acquiring an additional 328,918 shares in the last quarter. Finally, Logos Global Management LP increased its holdings in NextCure by 29.9% during the 2nd quarter. Logos Global Management LP now owns 2,500,000 shares of the company’s stock worth $3,975,000 after acquiring an additional 575,000 shares during the period. Hedge funds and other institutional investors own 42.65% of the company’s stock.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.